<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="bscl" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">bscl</book-part-id>
      <title-group>
        <title>Berardinelli-Seip Congenital Lipodystrophy</title>
        <alt-title alt-title-type="alt-title">Synonym: Berardinelli-Seip Congenital Generalized Lipodystrophy</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Van Maldergem</surname>
            <given-names>Lionel</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Centre de G&#x000e9;n&#x000e9;tique Humaine<break/>Universit&#x000e9; de Franche-Comt&#x000e9;<break/>Besan&#x000e7;on, France</aff>
          <email>vmald@skypro.be</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>8</day>
          <month>9</month>
          <year>2003</year>
        </date>
        <date date-type="updated">
          <day>8</day>
          <month>12</month>
          <year>2016</year>
        </date>
        <date date-type="revised">
          <day>23</day>
          <month>8</month>
          <year>2007</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="bws" document-type="chapter">Beckwith-Wiedemann Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="bvd" document-type="chapter">Best Vitelliform Macular Dystrophy</related-object>
      <abstract id="bscl.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Berardinelli-Seip congenital lipodystrophy (BSCL) is usually diagnosed at birth or soon thereafter. Because of the absence of functional adipocytes, lipid is stored in other tissues, including muscle and liver. Affected individuals develop insulin resistance and approximately 25%-35% develop diabetes mellitus between ages 15 and 20 years. Hepatomegaly secondary to hepatic steatosis and skeletal muscle hypertrophy occur in all affected individuals. Hypertrophic cardiomyopathy is reported in 20%-25% of affected individuals and is a significant cause of morbidity from cardiac failure and early mortality.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of BSCL is established in a proband with three <xref ref-type="sec" rid="bscl.Major_Criteria">major criteria</xref> or two major criteria plus two or more <xref ref-type="sec" rid="bscl.Minor_Criteria">minor criteria</xref> and/or by the identification of biallelic pathogenic variants in <italic toggle="yes">AGPAT2</italic> or <italic toggle="yes">BSCL2</italic>.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Restriction of total fat intake between 20% and 30% of total dietary energy maintains normal triglyceride serum concentration. Leptin therapy for treatment of hypertriglyceridemia and diabetes may be considered. Diabetes mellitus is managed as in childhood-onset diabetes mellitus.</p>
          <p><italic toggle="yes">Surveillance</italic>: Regular screening for glycosuria as a manifestation of diabetes mellitus, which usually starts in the teens (average age 12 years) but has also been described in infancy; monitoring for potential retinal, peripheral nerve, and renal complications of diabetes mellitus; yearly echocardiogram; yearly or biennial liver ultrasound examination to detect fatty infiltration.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Excessive dietary fat intake.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>BSCL is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="bscl.Diagnosis">
        <title>Diagnosis</title>
        <sec id="bscl.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Berardinelli-Seip congenital lipodystrophy (BSCL) <bold>should be suspected</bold> in individuals with one or more of the following major and/or minor findings.</p>
          <sec id="bscl.Major_Criteria">
            <title>Major Criteria</title>
            <p><bold>Lipoatrophy affecting the trunk, limbs, and face.</bold> Generalized lipodystrophy is apparent at birth. In some individuals, the face may be normal at birth with lipoatrophy becoming apparent during the first months of life. Lipoatrophy gives an athletic appearance, especially because skeletal muscle hypertrophy is also present.</p>
            <p><bold>Acromegaloid features</bold> include gigantism, muscular hypertrophy, advanced bone age, prognathism, prominent orbital ridges, enlarged hands and feet, clitoromegaly, and enlarged external genitalia in males.</p>
            <p><bold>Hepatomegaly.</bold> Liver enlargement is secondary to fatty liver early on and to cirrhosis late in the disease course.</p>
            <p><bold>Elevated serum concentration of triglycerides.</bold> Serum concentration of triglycerides can be elevated up to 80 g/L, and is sometimes associated with hypercholesterolemia.</p>
            <p><bold>Insulin resistance.</bold> Elevated serum concentrations of insulin and C-peptide may occur starting in the first years of life. Its early clinical expression is acanthosis nigricans of the groin, neck, and axillae, which may have, in some cases, a verrucous appearance.</p>
          </sec>
          <sec id="bscl.Minor_Criteria">
            <title>Minor Criteria</title>
            <p><bold>Hypertrophic cardiomyopathy</bold> may be present in infancy or develop later in life.</p>
            <p><bold>Psychomotor retardation or mild (IQ 50-70) to moderate (IQ 35-50) intellectual impairment.</bold> See <xref ref-type="sec" rid="bscl.Phenotype_Correlations_by_Gene">Phenotype Correlations by Gene</xref>.</p>
            <p><bold>Hirsutism</bold> manifests with low frontal and posterior hairline; hypertrichosis is apparently independent of hormonal stimulation.</p>
            <p><bold>Precocious puberty in females.</bold> In a series of 75 individuals with BSCL, three females underwent puberty before age seven years [<xref ref-type="bibr" rid="bscl.REF.van_maldergem.2002.722">Van Maldergem et al 2002</xref>].</p>
            <p><bold>Bone cysts</bold> occur in 8%-20% of affected individuals and have a polycystic appearance on x-ray. Located in the epiphyseal and metaphyseal regions of the long bones, bone cysts are often diagnosed during the second decade and are mostly observed in individuals with biallelic pathogenic variants in <italic toggle="yes">AGPAT2</italic>.</p>
            <p><bold>Phlebomegaly.</bold> Prominence of the veins of the lower and upper limbs is observed, in part because of the lack of subcutaneous fat.</p>
          </sec>
        </sec>
        <sec id="bscl.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of BSCL <bold>is established</bold> in a proband with three <xref ref-type="sec" rid="bscl.Major_Criteria">major criteria</xref> or two major criteria plus two or more <xref ref-type="sec" rid="bscl.Minor_Criteria">minor criteria</xref>
<bold>and/or</bold> by the identification of biallelic pathogenic variants in one of the genes listed in <xref ref-type="table" rid="bscl.T.molecular_genetic_testing_used_in">Table 1</xref>.</p>
          <p>Molecular testing approaches can include <bold>serial single-gene testing</bold>, use of a <bold>multi-gene panel</bold>, and <bold>more comprehensive</bold>
<bold>genomic testing</bold>.</p>
          <p>
            <bold>Serial single-gene testing</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>In individuals with intellectual disability or cardiomyopathy, sequencing of <italic toggle="yes">BSCL2</italic> should be considered first.</p>
            </list-item>
            <list-item>
              <p>The order of molecular genetic testing may also be stratified by the ethnicity of the affected individual (see <xref ref-type="table" rid="bscl.T.molecular_genetic_testing_used_in">Table 1</xref>, footnotes 5, 6, 8 and 9).</p>
            </list-item>
          </list>
          <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">AGPAT2</italic> and <italic toggle="yes">BSCL2</italic> and other genes of interest (see <xref ref-type="sec" rid="bscl.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included and the sensitivity of multi-gene panels vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests.</p>
          <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
          <p><bold>More comprehensive genomic testing</bold> (when available) including exome sequencing and genome sequencing may be considered if serial single-gene testing (and/or use of a multi-gene panel that includes <italic toggle="yes">AGPAT2</italic> and <italic toggle="yes">BSCL2</italic>) fails to confirm a diagnosis in an individual with features of BSCL. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation). For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
          <table-wrap id="bscl.T.molecular_genetic_testing_used_in" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in Berardinelli-Seip Congenital Lipodystrophy</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_1_2">Proportion of BSCL Attributed to Pathogenic Variants in This Gene</th>
                  <th id="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Test Method</th>
                </tr>
                <tr>
                  <th headers="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Sequence analysis&#x000a0;<sup>3</sup></th>
                  <th headers="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>4</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">AGPAT2</italic>
                  </td>
                  <td headers="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">See footnote 5</td>
                  <td headers="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">See footnote 6</td>
                  <td headers="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                </tr>
                <tr>
                  <td headers="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">BSCL2</italic>
                  </td>
                  <td headers="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">See footnote 8</td>
                  <td headers="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">See footnote 9</td>
                  <td headers="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">See footnote 10</td>
                </tr>
                <tr>
                  <td headers="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unknown&#x000a0;<sup>11</sup></td>
                  <td headers="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_2_1 hd_h_bscl.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" colspan="2" align="left" rowspan="1">NA</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="bscl.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="bscl" object-id="bscl.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="bscl.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="bscl.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="bscl.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="bscl.TF.1.4">
                <label>4. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used can include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="bscl.TF.1.5">
                <label>5. </label>
                <p><italic toggle="yes">AGPAT2</italic> pathogenic variants accounted for the majority of affected individuals (26/45) in a study from the US [<xref ref-type="bibr" rid="bscl.REF.agarwal.2003.4840">Agarwal et al 2003</xref>]. Individuals with biallelic pathogenic variants in <italic toggle="yes">AGPAT2</italic> have been described worldwide, with clusters in sub-Saharan Africa, Brazil, Maghreb (Morocco, Algeria, and Tunisia) and occasionally Middle Eastern countries (e.g., Turkey) and northern Europe [<xref ref-type="bibr" rid="bscl.REF.van_maldergem.2002.722">Van Maldergem et al 2002</xref>].</p>
              </fn>
              <fn id="bscl.TF.1.6">
                <label>6. </label>
                <p>Nearly all individuals of African origin with BSCL have the <italic toggle="yes">AGPAT2</italic>
<xref ref-type="table" rid="bscl.T.selected_agpat2_pathogenic_varian">c.589-2A&#x0003e;G</xref> pathogenic variant. Other pathogenic variants have now been described worldwide in diverse populations.</p>
              </fn>
              <fn id="bscl.TF.1.7">
                <label>7. </label>
                <p>No data on detection rate of gene-targeted deletion/duplication analysis are available.</p>
              </fn>
              <fn id="bscl.TF.1.8">
                <label>8. </label>
                <p>Pathogenic variants in <italic toggle="yes">BSCL2</italic> account for the majority of cases in the Berardinelli-Seip study group [<xref ref-type="bibr" rid="bscl.REF.van_maldergem.2002.722">Van Maldergem et al 2002</xref>, <xref ref-type="bibr" rid="bscl.REF.magr_.2003.1573">Magr&#x000e9; et al 2003</xref>] in which affected individuals originated mostly from Europe, the Middle East, and sub-Saharan Africa; studies from Brazil draw similar conclusions (18/26) [<xref ref-type="bibr" rid="bscl.REF.fu.2004.2916">Fu et al 2004</xref>, <xref ref-type="bibr" rid="bscl.REF.miranda.2009.512">Miranda et al 2009</xref>]; likewise, in a small sample from Japan, three of four affected individuals were homozygous for a <italic toggle="yes">BSCL2</italic> pathogenic variant [<xref ref-type="bibr" rid="bscl.REF.ebihara.2004.2360">Ebihara et al 2004</xref>].</p>
              </fn>
              <fn id="bscl.TF.1.9">
                <label>9. </label>
                <p><italic toggle="yes">BSCL2</italic> frameshift variant <xref ref-type="table" rid="bscl.T.selected_bscl2_pathogenic_variant">c.317_321delATCGT</xref> is identified in the Lebanese population [<xref ref-type="bibr" rid="bscl.REF.magr_.2001.365">Magr&#x000e9; et al 2001</xref>]. Other pathogenic variants are identified in individuals of European, Middle Eastern, Asian, or Portuguese ancestry.</p>
              </fn>
              <fn id="bscl.TF.1.10">
                <label>10. </label>
                <p>One large deletion and one large indel have been reported [<xref ref-type="bibr" rid="bscl.REF.magr_.2001.365">Magr&#x000e9; et al 2001</xref>].</p>
              </fn>
              <fn id="bscl.TF.1.11">
                <label>11. </label>
                <p><xref ref-type="bibr" rid="bscl.REF.magr_.2003.1573">Magr&#x000e9; et al [2003]</xref> found that 92/94 affected individuals harbor pathogenic variants that are either in <italic toggle="yes">BSCL2</italic> or <italic toggle="yes">AGPAT2</italic> or appear to be linked to their loci; <xref ref-type="bibr" rid="bscl.REF.agarwal.2004.336">Agarwal et al [2004]</xref> found this to be the case in 44/47 affected persons. Other reports provide evidence for at least two additional loci associated with congenital generalized lipodystrophy and other findings, resulting from biallelic pathogenic variants in <italic toggle="yes">CAV1</italic> or <italic toggle="yes">CAVIN1</italic> (formerly <italic toggle="yes">PTRF</italic>) respectively (see <xref ref-type="sec" rid="bscl.Differential_Diagnosis">Differential Diagnosis</xref>) [<xref ref-type="bibr" rid="bscl.REF.kim.2008.1129">Kim et al 2008</xref>, <xref ref-type="bibr" rid="bscl.REF.simha.2008.2318">Simha et al 2008</xref>, <xref ref-type="bibr" rid="bscl.REF.hayashi.2009.2623">Hayashi et al 2009</xref>, <xref ref-type="bibr" rid="bscl.REF.shastry.2010.2245">Shastry et al 2010</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="bscl.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="bscl.Clinical_Description">
          <title>Clinical Description</title>
          <p>Berardinelli-Seip congenital lipodystrophy (BSCL) is mostly diagnosed at birth or soon thereafter. Severe forms of BSCL may have prenatal onset with intrauterine growth retardation. Presentation in the first months of life includes failure to thrive (or conversely gigantism), hepatomegaly, lipoatrophy, facial dysmorphia, enlarged tongue, or developmental delay. All children with the neonatal or infantile presentation demonstrate lipoatrophy in the first year of life.</p>
          <p>Affected adults may first be seen in the plastic surgery clinic seeking cosmetic improvement of facial lipoatrophy or in the cardiology clinic or gastroenterology clinic for manifestations such as hypertrophic cardiomyopathy or hepatomegaly.</p>
          <p>
            <bold>Endocrinologic findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Affected individuals develop insulin resistance and approximately 25%-35% of individuals develop diabetes mellitus, most commonly between the ages 15 and 20 years. Diabetes mellitus:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Can be difficult to control;</p>
                </list-item>
                <list-item>
                  <p>Manifests by weight loss, polydipsia, polyuria, or asthenia and is frequently the presenting finding in the second decade;</p>
                </list-item>
                <list-item>
                  <p>Presents on occasion in early adulthood.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Some women present with oligomenorrhea, amenorrhea, or features of polycystic ovary syndrome.</p>
            </list-item>
          </list>
          <p><bold>Hypertrophic cardiomyopathy</bold> is reported in 20%-25% of individuals and is a significant cause of morbidity from cardiac failure and early mortality around age 30 years.</p>
          <list list-type="bullet">
            <list-item>
              <p>Three children of Pakistani, Chinese, and Turkish ancestry, respectively, came to medical attention in the first year of life with cardiac failure associated with hypertrophic cardiomyopathy [<xref ref-type="bibr" rid="bscl.REF.friguls.2009.14">Friguls et al 2009</xref>, <xref ref-type="bibr" rid="bscl.REF.jeninga.2012.47">Jeninga et al 2012</xref>, <xref ref-type="bibr" rid="bscl.REF.debray.2013.227">Debray et al 2013</xref>].</p>
            </list-item>
            <list-item>
              <p>Affected individuals have died as early as age 19 months of complications of cardiomyopathy.</p>
            </list-item>
          </list>
          <p><bold>Hepatic findings.</bold> Because of the absence of functional adipocytes, lipid is stored in other tissues including liver. Hepatomegaly secondary to hepatic steatosis occurs in virtually all individuals with BSCL.</p>
          <p><bold>Intellectual impairment</bold> is common; intrafamilial variability, including variability in intellectual impairment, exists.</p>
          <p><bold>Skeletal muscle</bold> hypertrophy occurs in all affected individuals as a result of lipid storage in skeletal muscle.</p>
        </sec>
        <sec id="bscl.Phenotype_Correlations_by_Gene">
          <title>Phenotype Correlations by Gene</title>
          <p><bold><italic toggle="yes">BSCL2.</italic></bold> Approximately 80% of individuals with biallelic pathogenic variants in <italic toggle="yes">BSCL2</italic> have mild-to-moderate intellectual impairment, whereas only 10% of individuals with biallelic pathogenic variants in <italic toggle="yes">AGPAT2</italic> have intellectual impairment.</p>
        </sec>
        <sec id="bscl.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p><bold><italic toggle="yes">AGPAT2.</italic></bold> No relationship appears to exist between the site and type of <italic toggle="yes">AGPAT2</italic> pathogenic variants and severity of lipodystrophy or metabolic complications.</p>
          <p><bold><italic toggle="yes">BSCL2.</italic></bold> With one exception (see following), no correlation between the site and type of a <italic toggle="yes">BSCL2</italic> pathogenic variant and phenotype (including intellectual impairment) has been observed [<xref ref-type="bibr" rid="bscl.REF.van_maldergem.2002.722">Van Maldergem et al 2002</xref>]. Furthermore, related and unrelated individuals with the same pathogenic variant may be discordant for intellectual impairment.</p>
          <p>A severe form of BSCL characterized by lipodystrophy followed after a couple of months by neurologic regression and death has been described in five infants in Spain [<xref ref-type="bibr" rid="bscl.REF.guill_nnavarro.2013.401">Guill&#x000e9;n-Navarro et al 2013</xref>]. Affected infants were either homozygous for the <italic toggle="yes">BSCL2</italic> pathogenic <xref ref-type="table" rid="bscl.T.selected_bscl2_pathogenic_variant">c.793C&#x0003e;T</xref> variant or had this pathogenic variant in combination with another pathogenic variant on the other allele. The pathogenic c.793C&#x0003e;T variant causes exon 7 skipping.</p>
        </sec>
        <sec id="bscl.Nomenclature">
          <title>Nomenclature</title>
          <p>Berardinelli-Seip syndrome is named after W Berardinelli, who reported the first affected individuals from Brazil in 1954. The syndrome was confirmed in 1959 in Norway by Martin Seip, whose affected population originated from the county of Rogaland. In the European literature, the terms Seip syndrome, generalized lipodystrophy, congenital generalized lipodystrophy, or total lipodystrophy have been used.</p>
          <p>Brunzell syndrome is the association of bone cysts and lipoatrophic diabetes mellitus described in five affected African Americans from the same sibship. Originally Brunzell syndrome was thought to be a separate entity, but it is now generally recognized that bone cysts represent a rare complication of Berardinelli-Seip congenital lipodystrophy. Furthermore, <xref ref-type="bibr" rid="bscl.REF.fu.2004.2916">Fu et al [2004]</xref> identified biallelic pathogenic variants in <italic toggle="yes">AGPAT2</italic> in three sibs with Brunzell syndrome.</p>
          <p>After onset of diabetes mellitus, some have termed individuals with BSCL as having "lipoatrophic diabetes."</p>
          <p>Lawrence syndrome is synonymous with acquired generalized lipodystrophy [<xref ref-type="bibr" rid="bscl.REF.garg.2011.3313">Garg 2011</xref>].</p>
        </sec>
        <sec id="bscl.Prevalence">
          <title>Prevalence</title>
          <p>More than three hundred cases of BSCL have been reported in the medical literature. Prevalence estimates</p>
          <list list-type="bullet">
            <list-item>
              <p>USA: 1:10,000,000 [<xref ref-type="bibr" rid="bscl.REF.agarwal.2006.175">Agarwal &#x00026; Garg 2006</xref>]</p>
            </list-item>
            <list-item>
              <p>Norway: 1:1,000,000</p>
            </list-item>
            <list-item>
              <p>Lebanon: 1:200,000</p>
            </list-item>
            <list-item>
              <p>Portugal: 1:500,000</p>
            </list-item>
            <list-item>
              <p>Sultanate of Oman: 1:25,000 [<xref ref-type="bibr" rid="bscl.REF.rajab.2005.27">Rajab et al 2005</xref>]</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="bscl.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><bold><italic toggle="yes">AGPAT2.</italic></bold> No other phenotypes are associated with pathogenic variants in <italic toggle="yes">AGPAT2</italic>, assuming that Brunzell syndrome is classic BSCL with one of its late complications, bone cysts.</p>
        <p><bold><italic toggle="yes">BSCL2.</italic></bold> Heterozygous missense variants in <italic toggle="yes">BSCL2</italic> have been identified in <related-object link-type="booklink" source-id="gene" document-id="spg17" document-type="chapter"><italic toggle="yes">BSCL2</italic>-related neurologic disorders</related-object>, a spectrum of conditions that includes: <related-object link-type="booklink" source-id="gene" document-id="cmt2" document-type="chapter">Charcot-Marie-Tooth disease type 2</related-object>, distal hereditary motor neuropathy type V, spastic paraplegia 17, and Silver syndrome [<xref ref-type="bibr" rid="bscl.REF.windpassinger.2004.271">Windpassinger et al 2004</xref>]. The clinical features of these <italic toggle="yes">BSCL2</italic>-related neurologic disorders include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Onset of symptoms ranging from the first to the seventh decade (6-66 years; mean: 19 years)</p>
          </list-item>
          <list-item>
            <p>Slow disease progression</p>
          </list-item>
          <list-item>
            <p>Upper-motor neuron involvement: gait disturbance with pyramidal signs ranging from mild to severe spasticity with hyperreflexia in the lower limbs and variable extensor plantar responses</p>
          </list-item>
          <list-item>
            <p>Lower motor neuron involvement: amyotrophy (wasting) of the peroneal muscles and the small muscles of the hand (particularly the thenar and interosseus dorsalis I muscles) that is frequently unilateral</p>
          </list-item>
          <list-item>
            <p>Usually normal sensation except for pallesthesia (i.e., abnormal vibration sense)</p>
          </list-item>
          <list-item>
            <p>Pes cavus and other foot deformities</p>
          </list-item>
          <list-item>
            <p>Autosomal dominant inheritance</p>
          </list-item>
        </list>
      </sec>
      <sec id="bscl.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><bold>Congenital generalized lipodystrophy 3 (CGL3)</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/612526">612526</ext-link>). Individuals with this condition typically have serum creatine kinase concentrations between 2.5 to ten times the upper limit of normal in addition to features resembling classic BSCL [<xref ref-type="bibr" rid="bscl.REF.kim.2008.1129">Kim et al 2008</xref>]. Two sibs of Hispanic ancestry with a homozygous <italic toggle="yes">CAV1</italic> pathogenic missense variant and hypotonia, elevated serum creatine kinase, atlas-axis instability, and generalized lipodystrophy have been described [<xref ref-type="bibr" rid="bscl.REF.simha.2008.2318">Simha et al 2008</xref>].</p>
        <p><bold>Congenital generalized lipodystrophy 4 (CGL4)</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/613327">613327</ext-link>). Generalized lipodystrophy, distal myopathy, muscular hypertrophy, hypertriglyceridemia, insulin resistance, elevated serum creatine kinase concentration, and normal intelligence were described in five Japanese individuals with pathogenic variants in <italic toggle="yes">CAVIN1</italic> (formerly <italic toggle="yes">PTRF</italic>), encoding polymerase I and transcript release factor [<xref ref-type="bibr" rid="bscl.REF.hayashi.2009.2623">Hayashi et al 2009</xref>]. A series of affected individuals with cardiac arrhythmia originating from Oman and the UK were reported by <xref ref-type="bibr" rid="bscl.REF.rajab.2010.e1000874">Rajab et al [2010]</xref>. The polymerase I and transcript release factor protein is thought to play an essential role in the formation of caveolae (invaginations of the plasma membrane involved in many cellular processes, including clathrin-independent endocytosis, cholesterol transport, and signal transduction) and the stabilization of caveolins, proteins present in the caveolae. These data confirm caveolin deficiency as a cause of the lipodystrophic process.</p>
        <p><bold>Further diagnoses to consider</bold> include the following:</p>
        <p>
          <bold>In infancy</bold>
        </p>
        <list list-type="bullet">
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="short" document-type="chapter">SHORT syndrome</related-object>
            </p>
          </list-item>
          <list-item>
            <p>Neonatal progeroid syndrome (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/264090">264090</ext-link>)</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="marfan" document-type="chapter">Marfan syndrome</related-object>, progeroid subtype, caused by pathogenic variants at the C-terminus of <italic toggle="yes">FBN1</italic> [<xref ref-type="bibr" rid="bscl.REF.graulneumann.2010.2749">Graul-Neumann et al 2010</xref>]</p>
          </list-item>
          <list-item>
            <p>Neurometabolic lysosomal storage disorders: <related-object link-type="booklink" source-id="gene" document-id="gaucher" document-type="chapter">Gaucher disease type 2</related-object>, <related-object link-type="booklink" source-id="gene" document-id="krabbe" document-type="chapter">Krabbe disease</related-object></p>
          </list-item>
          <list-item>
            <p>Russell diencephalic syndrome</p>
          </list-item>
          <list-item>
            <p>Leprechaunism: Donohue syndrome (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/246200">246200</ext-link>)</p>
          </list-item>
        </list>
        <p>
          <bold>In childhood</bold>
        </p>
        <list list-type="bullet">
          <list-item>
            <p>Familial partial Dunnigan-Ko&#x000eb;berling lipodystrophy (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/151660">151660</ext-link>)</p>
          </list-item>
          <list-item>
            <p>Rabson-Mendenhall syndrome (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/262190">262190</ext-link>)</p>
          </list-item>
          <list-item>
            <p>Insulin-dependent diabetes mellitus</p>
          </list-item>
          <list-item>
            <p>Acquired generalized lipodystrophy (Lawrence syndrome) [<xref ref-type="bibr" rid="bscl.REF.misra.2003.129">Misra &#x00026; Garg 2003</xref>]. Three subtypes exist.</p>
          </list-item>
          <list-item>
            <p>Mandibuloacral dysplasia (MAD) caused by <italic toggle="yes">LMNA/C</italic> and <italic toggle="yes">ZMPSTE24</italic> pathogenic variants (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/phenotypicSeries/PS248370">Mandibuloacral dysplasia with lipodystrophy: OMIM Phenotypic Series</ext-link>)</p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="hgps" document-type="chapter">Hutchinson-Gilford progeria syndrome</related-object>
            </p>
          </list-item>
        </list>
        <p>
          <bold>In adulthood</bold>
        </p>
        <list list-type="bullet">
          <list-item>
            <p>Acquired partial lipodystrophy (Barraquer-Simons syndrome) (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/608709">608709</ext-link>)</p>
          </list-item>
          <list-item>
            <p>Lipodystrophy associated with human immunodeficiency virus infection</p>
          </list-item>
          <list-item>
            <p>Partial lipodystrophy with C3 nephritic factor (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/613913">613913</ext-link>)</p>
          </list-item>
          <list-item>
            <p>Acquired generalized lipodystrophy (Lawrence syndrome)</p>
          </list-item>
        </list>
        <p>See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/phenotypicSeries/PS608594">Lipodystrophy, congenital generalized: OMIM Phenotypic Series</ext-link> to view genes associated with this phenotype in OMIM.</p>
      </sec>
      <sec id="bscl.Management">
        <title>Management</title>
        <sec id="bscl.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with Berardinelli-Seip congenital lipodystrophy (BSCL), the following clinical evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Complete blood count</p>
            </list-item>
            <list-item>
              <p>Serum concentration of electrolytes, AST, alanine transaminase, urea, creatinine, insulin, C-peptide, triglycerides, and cholesterol</p>
            </list-item>
            <list-item>
              <p>Oral glucose tolerance test; when appropriate, clamp glucose homeostasis study</p>
            </list-item>
            <list-item>
              <p>Ultrasound of the liver to evaluate liver size and fatty content</p>
            </list-item>
            <list-item>
              <p>Echocardiogram to evaluate for cardiac hypertrophy</p>
            </list-item>
            <list-item>
              <p>Renal ultrasound examination to evaluate for kidney size</p>
            </list-item>
            <list-item>
              <p>Physical examination for orthopedic complications including reduced hip mobility and genu valgum</p>
            </list-item>
            <list-item>
              <p>Skeletal survey, especially of the long bones, to evaluate for bone cysts</p>
            </list-item>
            <list-item>
              <p>Bone age and assessment of sexual maturity rating/pubertal status</p>
            </list-item>
            <list-item>
              <p>Complete ophthalmologic examination, including slit lamp examination, to evaluate for ophthalmologic complications due to hyperlipemia and/or diabetes mellitus</p>
            </list-item>
            <list-item>
              <p>Assessment of cognitive ability with age-appropriate scales</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="bscl.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Restriction of total fat intake between 20% and 30% of total dietary energy is often sufficient to maintain normal triglyceride serum concentration.</p>
          <p>Fibric acid derivatives and n-3 polyunsaturated fatty acids derived from fish oils can be tried for the treatment of extreme hypertriglyceridemia.</p>
          <p>Leptin treatment has proven successful in controlling both hypertriglyceridemia and diabetes mellitus [<xref ref-type="bibr" rid="bscl.REF.garg.1999.3390">Garg et al 1999</xref>, <xref ref-type="bibr" rid="bscl.REF.beltrand.2007.e291">Beltrand et al 2007</xref>, <xref ref-type="bibr" rid="bscl.REF.ebihara.2007.532">Ebihara et al 2007</xref>]. Despite the absence of well-controlled randomized studies that could provide a more thorough assessment of the possible adverse effects of leptin therapy, the United States Food and Drug Administration granted approval of leptin administration [<xref ref-type="bibr" rid="bscl.REF.tsoukas.2015.47">Tsoukas et al 2015</xref>].</p>
          <p>Management of diabetes mellitus does not differ from that of childhood-onset diabetes mellitus.</p>
          <p>Special education is required for individuals with psychomotor retardation or intellectual disability.</p>
        </sec>
        <sec id="bscl.Prevention_of_Primary_Manifestation">
          <title>Prevention of Primary Manifestations</title>
          <p>Dietary restriction of total fat intake may prevent hypertriglyceridemia (see <xref ref-type="sec" rid="bscl.Treatment_of_Manifestations">Treatment of Manifestations</xref>).</p>
        </sec>
        <sec id="bscl.Surveillance">
          <title>Surveillance</title>
          <p>The following are appropriate:</p>
          <list list-type="bullet">
            <list-item>
              <p>Periodic screening for glycosuria as a manifestation of diabetes mellitus</p>
            </list-item>
            <list-item>
              <p>For individuals with diabetes mellitus, follow-up in a diabetes clinic every six months to monitor for possible retinal, peripheral nerve, and renal complications</p>
            </list-item>
            <list-item>
              <p>Yearly cardiac ultrasound and EKG</p>
            </list-item>
            <list-item>
              <p>Yearly or biennial liver ultrasound examination to detect fatty infiltration</p>
              <p>Ultrasound surveillance is a noninvasive procedure that can, along with serum lipid concentrations and liver enzymes, provide information on the degree of lipid control and compliance with the fat-restricted diet.</p>
            </list-item>
          </list>
        </sec>
        <sec id="bscl.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Excessive dietary fat intake should be avoided.</p>
        </sec>
        <sec id="bscl.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="bscl.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="bscl.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Affected pregnant women should be followed in a high-risk pregnancy care unit by a multidisciplinary team including a specialist in fetal medicine and an expert in diabetic management. Pregnancy may increase the risk of diabetic decompensation. Babies born to women with diabetes are at an increased risk for fetal anomalies and postnatal complications compared to babies born to women without diabetes.</p>
        </sec>
        <sec id="bscl.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
        <sec id="bscl.Other">
          <title>Other</title>
          <p>Other drugs, including fenfluramine, have no proven efficacy and should be avoided.</p>
        </sec>
      </sec>
      <sec id="bscl.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="bscl.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Berardinelli-Seip congenital lipodystrophy (BSCL) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="bscl.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one BSCL-related pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic; increased incidence of diabetes mellitus has been suggested but never confirmed.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic, although increased incidence of diabetes mellitus is suggested.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with BSCL are obligate heterozygotes (carriers) for a BSCL-related pathogenic variant:</p>
          <list list-type="bullet">
            <list-item>
              <p>Pregnancies in individuals with BSCL type 1 have been described [<xref ref-type="bibr" rid="bscl.REF.van_maldergem.2002.722">Van Maldergem et al 2002</xref>].</p>
            </list-item>
            <list-item>
              <p>Many individuals with BSCL type 2 (BSCL2) do not reproduce.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier of a BSCL-related pathogenic variant.</p>
        </sec>
        <sec id="bscl.Carrier_Heterozygote_Detection">
          <title>Carrier (Heterozygote) Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the BSCL-related pathogenic variants in the family.</p>
        </sec>
        <sec id="bscl.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>Differentiation between BSCL type 1 and BSCL type 2 may be useful for purposes of genetic counseling, particularly if the affected individual is too young for cognitive development to have been clearly characterized.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="bscl.Prenatal_Testing_and_Preimplantatio">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the BSCL-related pathogenic variants have been identified in an affected family member, prenatal testing and preimplantation genetic diagnosis for a pregnancy at increased risk for BSCL are possible.</p>
        </sec>
      </sec>
      <sec id="bscl.Resources">
        <title>Resources</title>
      </sec>
      <sec id="bscl.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="bscl.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Pathogenic variants in <italic toggle="yes">AGPAT2,</italic> encoding AGPAT2, and <italic toggle="yes">BSCL2</italic>, encoding seipin, cause BSCL. AGPAT2 (1-acyl-sn-glycerol-3-phosphate acyltransferase beta) is a key enzyme in the biosynthesis of triglycerides. Seipin, which is less well understood, is predicted to play a role in the maintenance and formation of lipid-containing vesicles.</p>
          <sec id="bscl.AGPAT2">
            <title>
              <italic toggle="yes">AGPAT2</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">AGPAT2</italic> consists of six exons spanning less than 20 kb. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="bscl" object-id="bscl.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic variants.</bold> Homozygous or compound heterozygous <italic toggle="yes">AGPAT2</italic> variants are associated with BSCL. <xref ref-type="bibr" rid="bscl.REF.agarwal.2002.21">Agarwal et al [2002]</xref> identified various <italic toggle="yes">AGPAT2</italic> variants in 11 pedigrees, including a deletion resulting in a frameshift variant and premature termination codon, nonsense variants, splice site variants, missense variants, and single amino-acid deletions. <xref ref-type="bibr" rid="bscl.REF.magr_.2003.1573">Magr&#x000e9; et al [2003]</xref> also reported various pathogenic variants in 38 individuals from 30 pedigrees (for more information, see databases in <related-object source-id="gene" document-id="bscl" object-id="bscl.molgen.TA">Table A</related-object>).</p>
            <table-wrap id="bscl.T.selected_agpat2_pathogenic_varian" orientation="portrait" position="anchor">
              <label>Table 2. </label>
              <caption>
                <p>Selected <italic toggle="yes">AGPAT2</italic> Pathogenic Variants</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                    <th id="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                    <th id="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.183-2A&#x0003e;G<break/>(c.IVS1-2A&#x0003e;G)&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_3" rowspan="17" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/68835055">NM_006412.3</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/6041665">NP_006403.2</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.182+1G&#x0003e;A<break/>(c.IVS1+1G&#x0003e;A)</td>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.194G&#x0003e;A</td>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Trp65Ter</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.202C&#x0003e;T</td>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg68Ter</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.299G&#x0003e;A</td>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ser100Asn</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.335C&#x0003e;T</td>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Pro112Leu</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.492+1G&#x0003e;A<break/>(c.IVS3+1G&#x0003e;A)</td>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.493-1G&#x0003e;C<break/>(c.IVS3-1G&#x0003e;C)&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">del exon3 &#x02013; exon 4<break/>(c.del317_588)&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu107AlafsTer279</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.514G&#x0003e;A</td>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu172Lys</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.538delG<break/>(c.del538G)</td>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asp180ThrfsTer73</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.589-2A&#x0003e;G<break/>(c.IVS4-2A&#x0003e;G)&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.646A&#x0003e;T</td>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Lys216Ter</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.661+2T&#x0003e;G<break/>(c.IVS5+2T&#x0003e;G)</td>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.676C&#x0003e;T</td>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gln226Ter</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.713C&#x0003e;G</td>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala238Gly</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.755_763del9<break/>(c.del755_764)</td>
                    <td headers="hd_h_bscl.T.selected_agpat2_pathogenic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Met252_Thr254del</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the author. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
                <fn id="bscl.TF.2.1">
                  <label>1. </label>
                  <p>Variant designation that does not conform to current naming conventions</p>
                </fn>
                <fn id="bscl.TF.2.2">
                  <label>2. </label>
                  <p>Recurrent variant</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Normal gene product.</bold> The AGPAT2 protein, 1-acyl-sn-glycerol-3-phosphate acyltransferase beta (also known as lysophosphatidic acid acyltransferase beta [LPAAT]), has 278 amino acids and belongs to the family of acyltransferases. The AGPAT2 enzyme catalyzes an essential reaction in the biosynthetic pathway of glycerophospholipids and triacylglycerol [<xref ref-type="bibr" rid="bscl.REF.agarwal.2002.21">Agarwal et al 2002</xref>].</p>
            <p><bold>Abnormal gene product.</bold> Pathogenic variants in <italic toggle="yes">AGPAT2</italic> may cause congenital lipodystrophy by inhibiting/reducing triacylglycerol synthesis and storage in adipocytes. It is also likely that reduced AGPAT2 activity could increase tissue levels of lysophosphatidic acid, which may negatively affect adipocyte functions [<xref ref-type="bibr" rid="bscl.REF.agarwal.2002.21">Agarwal et al 2002</xref>].</p>
          </sec>
          <sec id="bscl.BSCL2">
            <title>
              <italic toggle="yes">BSCL2</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">BSCL2</italic> consists of 11 exons spanning at least 14 kb. The putative translation initiation codon is located in the second exon. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="bscl" object-id="bscl.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><italic toggle="yes">BSCL2</italic> has no significant homology to other known proteins. Multiple seipin transcripts of 1.8, 2.0, and 2.4 kb have been identified by RNA blot analysis. The 1.8- and 2.4-kb transcripts are ubiquitous whereas the 2.0 kb transcript is expressed selectively and at high levels in brain and testis. It has been postulated that this distribution could account for the intellectual disability, voracious appetite, and macrogenitosomia observed in BSCL type 2.</p>
            <p><bold>Pathogenic variants.</bold> Homozygous or compound heterozygous <italic toggle="yes">BSCL2</italic> variants are associated with BSCL. <xref ref-type="bibr" rid="bscl.REF.magr_.2001.365">Magr&#x000e9; et al [2001]</xref> identified several different variants in <italic toggle="yes">BSCL2</italic> among 44 individuals, including microdeletions, small insertions and deletions, and five nucleotide substitutions. The majority of pathogenic variants resulted in a frameshift or a premature stop codon (for more information, see databases in <related-object source-id="gene" document-id="bscl" object-id="bscl.molgen.TA">Table A</related-object>).</p>
            <table-wrap id="bscl.T.selected_bscl2_pathogenic_variant" orientation="portrait" position="anchor">
              <label>Table 3. </label>
              <caption>
                <p>Selected <italic toggle="yes">BSCL2</italic> Pathogenic Variants</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                    <th id="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                    <th id="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.142C&#x0003e;T</td>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu48Phe</td>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_3" rowspan="15" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/171906560">NM_032667.5</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/40068505">NP_116056.3</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.154_155dupTT<break/>(c.500_502insTT)</td>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr53SerfsTer40</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.193delCinsGGA<break/>(c.537_538delCinsGGA)</td>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Pro65ArgfsTer28</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.317_321delATCGT<break/>(c.del659_663)</td>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr106CysfsTer6</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.325dupA<break/>(c.324_325 insA)</td>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr109AsnfsTer5</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.412C&#x0003e;T&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg138Ter</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.574-2A&#x0003e;G<break/>(c.IVS5-2A&#x0003e;G)</td>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.672-3C&#x0003e;G<break/>(c.IVS6-3C&#x0003e;G)</td>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.672-2A&#x0003e;C<break/>(c.IVS6-2 A&#x0003e;C)</td>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.672-2A&#x0003e;G<break/>(c.IVS6-2A&#x0003e;G)</td>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.671+5G&#x0003e;A<break/>(c.IVS6+5G&#x0003e;A)</td>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.634G&#x0003e;C</td>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala212Pro</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.782dupG<break/>(c.1126_1127insG)</td>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ile262HisfsTer12</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.793C&#x0003e;T</td>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg265Ter</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.823C&#x0003e;T</td>
                    <td headers="hd_h_bscl.T.selected_bscl2_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg275Ter</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the author. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
                <fn id="bscl.TF.3.1">
                  <label>1. </label>
                  <p>Variant designation that does not conform to current naming conventions</p>
                </fn>
                <fn id="bscl.TF.3.2">
                  <label>2. </label>
                  <p>Recurrent variant</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Normal gene product.</bold>
<italic toggle="yes">BSCL2</italic> encodes a 398-amino acid protein, seipin (isoform 2, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/40068505">NP_116056.3</ext-link>). Seipin has at least two hydrophobic amino acid stretches, indicating that it could be a transmembrane protein. The function of seipin is unknown [<xref ref-type="bibr" rid="bscl.REF.magr_.2001.365">Magr&#x000e9; et al 2001</xref>]; however, it is predicted to be a membrane protein mainly located in endoplasmic reticulum (ER) with a luminal loop domain and with both termini facing the cytoplasm [<xref ref-type="bibr" rid="bscl.REF.cartwright.2012.1042">Cartwright &#x00026; Goodman 2012</xref>].</p>
            <p>The seipin protein has a domain similar to that contained in the sterol element-binding proteins (SREBPs) which have a role in regulation of cholesterol biosynthesis and uptake. Study of yeast seipin indicates that it is located at the junction of ER and lipid droplets called adiposomes. When seipin is absent, irregularly shaped small lipid droplets replace these well-formed adiposomes, suggesting a role for seipin in the formation or maintenance of these lipid-containing vesicles.</p>
            <p>In addition, studies in mouse models indicate that reduction of seipin strongly reduced expression and synthesis of AGPAT2 and DGAT2, suggesting that seipin is located located upstream in the metabolic pathway[<xref ref-type="bibr" rid="bscl.REF.payne.2008.2055">Payne et al 2008</xref>, <xref ref-type="bibr" rid="bscl.REF.ito.2009.8">Ito &#x00026; Suzuki 2009</xref>].</p>
            <p>Seipin also occurs as another isoform. <italic toggle="yes">BSCL2</italic> also encodes a protein of 462 amino acids (isoform 1, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_001116427.1">NP_001116427.1</ext-link>) (vs 398 amino acids reported in the seminal paper); the 398-amino acid-based numbering is still used in order to avoid inconsistencies linked to re-numbering.</p>
            <p><bold>Abnormal gene product.</bold> The majority of <italic toggle="yes">BSCL2</italic> variants are null variants predicted to result in severe disruption of the protein function. Rare missense variants have been studied. One missense variant in seipin, p.Ala212Pro (found in affected individuals in Norway), resulted in mislocalization of adiposomes at the junction of nuclear membrane and ER. The p.Arg275Ter missense variant resulted in misshapen lipid droplets in their orthotopic ER localization [<xref ref-type="bibr" rid="bscl.REF.payne.2008.2055">Payne et al 2008</xref>]. More recently, a dual role for seipin &#x02013; both regulation of lipid homeostasis by inhibiting lipid droplets formation in non-adipocytes and promotion of adipogenesis &#x02013; has been postulated [<xref ref-type="bibr" rid="bscl.REF.wee.2014.583">Wee et al 2014</xref>].This putative adipogenic role of seipin would not give, at first glance, an explanation for the intellectual impairment often observed in individuals with BSCL. An interaction of seipin with neurotransmission could provide the basis of intellectual disability [<xref ref-type="bibr" rid="bscl.REF.wei.2013.478">Wei et al 2013</xref>].</p>
          </sec>
        </sec>
      </sec>
      <sec id="bscl.References">
        <title>References</title>
        <sec id="bscl.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="bscl.Literature_Cited.reflist0">
            <ref id="bscl.REF.agarwal.2002.21">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Agarwal</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arioglu</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Almeida</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akkoc</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>SI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowcock</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barnes</surname>
                    <given-names>RI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garg</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.</article-title>
                <source>Nat Genet</source>
                <volume>31</volume>
                <fpage>21</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">11967537</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.agarwal.2004.336">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Agarwal</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barnes</surname>
                    <given-names>RI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garg</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Genetic basis of congenital generalized lipodystrophy.</article-title>
                <source>Int J Obes Relat Metab Disord</source>
                <volume>28</volume>
                <fpage>336</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14557833</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.agarwal.2006.175">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Agarwal</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garg</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Genetic disorders of adipose tissue development, differentiation, and death.</article-title>
                <source>Annu Rev Genomics Hum Genet</source>
                <volume>7</volume>
                <fpage>175</fpage>
                <lpage>99</lpage>
                <pub-id pub-id-type="pmid">16722806</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.agarwal.2003.4840">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Agarwal</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simha</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oral</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moran</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gorden</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Rahilly</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zaidi</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gurakan</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arslanian</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ricker</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>NH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bindl</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herbst</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kennel</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Gazali</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garg</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy.</article-title>
                <source>J Clin Endocrinol Metab</source>
                <volume>88</volume>
                <fpage>4840</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">14557463</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.beltrand.2007.e291">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beltrand</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beregszaszi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chevenne</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sebag</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Kerdanet</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huet</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polak</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tubiana-Rufi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacombe</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Paoli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy-Marchal</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy.</article-title>
                <source>Pediatrics</source>
                <volume>120</volume>
                <fpage>e291</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17671040</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.cartwright.2012.1042">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cartwright</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodman</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Seipin: from human disease to molecular mechanism</article-title>
                <source>J Lipid Res</source>
                <volume>53</volume>
                <fpage>1042</fpage>
                <lpage>55</lpage>
                <pub-id pub-id-type="pmid">22474068</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.debray.2013.227">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Debray</surname>
                    <given-names>FG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baguette</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colinet</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Maldergem</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verellen-Dumoulin</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Early infantile cardiomyopathy and liver disease: a multisystemic disorder caused by congenital lipodystrophy.</article-title>
                <source>Mol Genet Metab</source>
                <volume>109</volume>
                <fpage>227</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">23647707</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.ebihara.2007.532">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ebihara</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kusakabe</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirata</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masuzaki</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyanaga</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanaka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chusho</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyazawa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hosoda</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DePaoli</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukushima</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakao</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.</article-title>
                <source>J Clin Endocrinol Metab</source>
                <volume>92</volume>
                <fpage>532</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">17118991</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.ebihara.2004.2360">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ebihara</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kusakabe</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masuzaki</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanaka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chusho</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyanaga</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyazawa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hosoda</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakao</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Gene and phenotype analysis of congenital generalized lipodystrophy in Japanese: a novel homozygous nonsense mutation in seipin gene.</article-title>
                <source>J Clin Endocrinol Metab</source>
                <volume>89</volume>
                <fpage>2360</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">15126564</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.friguls.2009.14">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Friguls</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coroleu</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>del Alcazar</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hilbert</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Maldergem</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pintos-Morell</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Severe cardiac phenotype of Berardinelli-Seip congenital lipodystrophy in an infant with homozygous E189X BSCL2 mutation.</article-title>
                <source>Eur J Med Genet</source>
                <volume>52</volume>
                <fpage>14</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">19041432</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.fu.2004.2916">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kazlauskaite</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baracho Mde</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santos</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brand&#x000e3;o-Neto</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villares</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Celi</surname>
                    <given-names>FS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wajchenberg</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shuldiner</surname>
                    <given-names>AR</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Mutations in Gng3lg and AGPAT2 in Berardinelli-Seip congenital lipodystrophy and Brunzell syndrome: phenotype variability suggests important modifier effects.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <volume>89</volume>
                <fpage>2916</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">15181077</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.garg.1999.3390">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Garg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barnes</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arioglu</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zaidi</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gurakan</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kocak</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Rahilly</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>SI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowcock</surname>
                    <given-names>AM</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>A gene for congenital generalized lipodystrophy maps to human chromosome 9q34.</article-title>
                <source>J Clin Endocrinol Metab</source>
                <volume>84</volume>
                <fpage>3390</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">10487716</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.garg.2011.3313">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Garg</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Clinical review#: Lipodystrophies: genetic and acquired body fat disorders.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <volume>96</volume>
                <fpage>3313</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">21865368</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.graulneumann.2010.2749">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Graul-Neumann</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kienitz</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>PN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baasanjav</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karow</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillessen-Kaesbach</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fahsold</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Passarge</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Marfan syndrome with neonatal progeroid syndrome-like lipodystrophy associated with a novel frameshift mutation at the 3' terminus of the FBN1-gene.</article-title>
                <source>Am J Med Genet A.</source>
                <year>2010</year>
                <volume>152A</volume>
                <fpage>2749</fpage>
                <lpage>55</lpage>
                <pub-id pub-id-type="pmid">20979188</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.guill_nnavarro.2013.401">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guill&#x000e9;n-Navarro</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>S&#x000e1;nchez-Iglesias</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Domingo-Jim&#x000e9;nez</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Victoria</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruiz-Riquelme</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>R&#x000e1;bano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loidi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beiras</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonz&#x000e1;lez-M&#x000e9;ndez</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramos</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>L&#x000f3;pez-Gonz&#x000e1;lez</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ballesta-Mart&#x000ed;nez</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garrido-Pumar</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aguiar</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruibal</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Requena</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ara&#x000fa;jo-Vilar</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>A new seipin-associated neurodegenerative syndrome.</article-title>
                <source>J Med Genet.</source>
                <year>2013</year>
                <volume>50</volume>
                <fpage>401</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">23564749</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.hayashi.2009.2623">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>YK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsuda</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tominaga</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitsuhashi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>Y-E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nonaka</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hino-Fukuyo</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haginoya</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugano</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishino</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Human PTFR mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy.</article-title>
                <source>J Clin Invest</source>
                <volume>119</volume>
                <fpage>2623</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">19726876</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.ito.2009.8">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Seipinopathy: a novel endoplasmic reticulum stress-associated disease.</article-title>
                <source>Brain</source>
                <volume>132</volume>
                <fpage>8</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">18790819</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.jeninga.2012.47">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jeninga</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Vroede</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamers</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Breur</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoeven-Duif</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berger</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalkhoven</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>a patient with congenital generalized lipodystrophy due to a novel mutation in BSCL2: indications for secondary mitochondrial dysfunction.</article-title>
                <source>JIMD Rep</source>
                <year>2012</year>
                <volume>4</volume>
                <fpage>47</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">23430896</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.kim.2008.1129">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Del&#x000e9;pine</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boutet</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>El Mourabit</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Lay</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meier</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nemani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bridel</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leite</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertola</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Semple</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Rahilly</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dugail</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Capeau</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lathrop</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magr&#x000e9;</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <volume>93</volume>
                <fpage>1129</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">18211975</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.magr_.2001.365">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Magr&#x000e9;</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Del&#x000e9;pine</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khallouf</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gedde-Dahl</surname>
                    <given-names>T</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Van Maldergem</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sobel</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papp</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meier</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e9;garban&#x000e9;</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bachy</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verloes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>d'Abronzo</surname>
                    <given-names>FH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seemanova</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Assan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baudic</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bourut</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Czernichow</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huet</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grigorescu</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Kerdanet</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacombe</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Labrune</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lanza</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loret</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsuda</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Navarro</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nivelon-Chevalier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polak</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robert</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tric</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tubiana-Rufi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vigouroux</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weissenbach</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savasta</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maassen</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trygstad</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bogalho</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freitas</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Medina</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnicci</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joffe</surname>
                    <given-names>BI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loyson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Panz</surname>
                    <given-names>VR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raal</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Rahilly</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stephenson</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kahn</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lathrop</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Capeau</surname>
                    <given-names>J</given-names>
                  </name>
                  <etal/>
                </person-group>
                <year>2001</year>
                <article-title>Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13.</article-title>
                <source>Nat Genet</source>
                <volume>28</volume>
                <fpage>365</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">11479539</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.magr_.2003.1573">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Magr&#x000e9;</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Del&#x000e9;pine</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Maldergem</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robert</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maassen</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meier</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Panz</surname>
                    <given-names>VR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tubiana-Rufi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Czernichow</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seemanova</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buchanan</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacombe</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vigouroux</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lascols</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kahn</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Capeau</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lathrop</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Prevalence of mutations in AGPAT2 among human lipodystrophies.</article-title>
                <source>Diabetes</source>
                <volume>52</volume>
                <fpage>1573</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12765973</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.miranda.2009.512">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Miranda</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wajchenberg</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calsolari</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aguiar</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silva</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribeiro</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fonseca</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amaral</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boson</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Resende</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Marco</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Novel mutations of the BSCL2 and AGPAT2 genes in 10 families with Berardinelli-Seip congenital generalized lipodystrophy syndrome.</article-title>
                <source>Clin Endocrinol (Oxf)</source>
                <volume>71</volume>
                <fpage>512</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">19226263</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.misra.2003.129">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Misra</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garg</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature.</article-title>
                <source>Medicine (Baltimore)</source>
                <volume>82</volume>
                <fpage>129</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">12640189</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.payne.2008.2055">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Payne</surname>
                    <given-names>VA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grimsey</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuthill</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gray</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dalla Nora</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Semple</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O&#x02019;Rahilly</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rochford</surname>
                    <given-names>JJ</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>The human lipodystrophy gene BSCL2/seipin may be essential for adipocyte normal differentiation.</article-title>
                <source>Diabetes</source>
                <volume>57</volume>
                <fpage>2055</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">18458148</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.rajab.2005.27">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rajab</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bappal</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Shaikh</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Khusaibi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohammed</surname>
                    <given-names>AJ</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Common autosomal recessive diseases in Oman derived from a hospital-based registry.</article-title>
                <source>Community Genet.</source>
                <volume>8</volume>
                <fpage>27</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">15767751</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.rajab.2010.e1000874">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rajab</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Straub</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCann</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seelow</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Varon</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barresi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schulze</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lucke</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>L&#x000fc;tzkendorf</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karbasiyan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bachmann</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spuler</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schuelke</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations.</article-title>
                <source>PLoS Genet</source>
                <volume>6</volume>
                <fpage>e1000874</fpage>
                <pub-id pub-id-type="pmid">20300641</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.shastry.2010.2245">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shastry</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delgado</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dirik</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turkmen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Agarwal</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garg</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations.</article-title>
                <source>Am J Med Genet A.</source>
                <year>2010</year>
                <volume>152A</volume>
                <fpage>2245</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">20684003</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.simha.2008.2318">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Simha</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Agarwal</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aronin</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iannaccone</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garg</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Novel subtype of congenital generalized lipodystrophy associated with muscular weakness and cervical spine instability.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>146A</volume>
                <fpage>2318</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">18698612</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.tsoukas.2015.47">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tsoukas</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farr</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mantzoros</surname>
                    <given-names>CS</given-names>
                  </name>
                </person-group>
                <article-title>Leptin in congenital and HIV-associated lipodystrophy.</article-title>
                <source>Metabolism.</source>
                <year>2015</year>
                <volume>64</volume>
                <fpage>47</fpage>
                <lpage>59</lpage>
                <pub-id pub-id-type="pmid">25267014</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.van_maldergem.2002.722">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Van Maldergem</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magr&#x000e9;</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khallouf</surname>
                    <given-names>TE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gedde-Dahl</surname>
                    <given-names>T</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Delepine</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trygstad</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seemanova</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stephenson</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Albott</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnici</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Panz</surname>
                    <given-names>VR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Medina</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bogalho</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huet</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savasta</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verloes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robert</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loret</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Kerdanet</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tubiana-Rufi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Megarbane</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maassen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polak</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacombe</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kahn</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silveira</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Abronzo</surname>
                    <given-names>FH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grigorescu</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lathrop</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Capeau</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Rahilly</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy.</article-title>
                <source>J Med Genet</source>
                <volume>39</volume>
                <fpage>722</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">12362029</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.wee.2014.583">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wee</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugii</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Han</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <article-title>Towards a mechanistic understanding of lipodystrophy and seipin function.</article-title>
                <source>Biosci Rep.</source>
                <year>2014</year>
                <volume>34</volume>
                <fpage>583</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">25195639</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.wei.2013.478">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wei</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xia</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ong</surname>
                    <given-names>WY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pang</surname>
                    <given-names>ZP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Han</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <article-title>Seipin regulates excitatory synaptic transmission in cortical neurons.</article-title>
                <source>J Neurochem.</source>
                <year>2013</year>
                <volume>124</volume>
                <fpage>478</fpage>
                <lpage>89</lpage>
                <pub-id pub-id-type="pmid">23173741</pub-id>
              </element-citation>
            </ref>
            <ref id="bscl.REF.windpassinger.2004.271">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Windpassinger</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Auer-Grumbach</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Irobi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petek</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horl</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reed</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dierick</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verpoorten</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warner</surname>
                    <given-names>TT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Proukakis</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van den Bergh</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verellen</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Maldergem</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merlini</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jonghe</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmerman</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crosby</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wagner</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome.</article-title>
                <source>Nat Genet</source>
                <volume>36</volume>
                <fpage>271</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">14981520</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="bscl.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="bscl.Suggested_Reading.reflist0">
            <ref id="bscl.REF.gomes.2009.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gomes</surname>
                    <given-names>KB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pardini</surname>
                    <given-names>VC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernandes</surname>
                    <given-names>AP</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Clinical and molecular aspects of Berardinelli-Seip congenital lipodystrophy.</article-title>
                <source>Clin Chim Acta.</source>
                <volume>402</volume>
                <fpage>1</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">19167372</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="bscl.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="bscl.Author_Notes">
          <title>Author Notes</title>
          <p>Dr. Van Maldergem is a teacher of Human Genetics with 25 years' experience in clinical genetics. He is the coordinator of the Berardinelli-Seip study group (created in 1993) and organizer of the first international conference on lipodystrophies (Brussels, 1997).</p>
        </sec>
        <sec id="bscl.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>8 December 2016 (ma) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>28 June 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>23 February 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>23 August 2007 (cd) Revision: sequence analysis and prenatal diagnosis for BSCL type 1 available on a clinical basis</p>
            </list-item>
            <list-item>
              <p>21 December 2005 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>3 August 2004 (lvm) Revision: Genetically Related Disorders</p>
            </list-item>
            <list-item>
              <p>8 September 2003 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>24 April 2003 (lvm) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
